Neurofeedback From the Supplementary Motor Area for Tourette Syndrome
ConditionTourette Syndrome in Adolescence
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age10-16
SponsorYale University
About this trial
This is a clinical trial where adolescents aged 10-16 years old with Tourette Syndrome (or chronic tic disorder) are randomized to receive either real-time functional magnetic resonance imaging (fMRI) neurofeedback targeting the supplementary motor area (for the experimental intervention) or real-time fMRI neurofeedback (NF) from a control region (for the control intervention).
Eligibility criteria
Qualifiers
Boys and girls, 10 to 16 years of age
A current diagnosis of Tourette Syndrome (TS) or chronic tic disorder (CTD), with active tics that can be executed without head movement, and a YGTSS score of at least 13 (for TS participants) or at least 12 (for CTD participants)
Currently stable medication treatment and no planned changes in medication for the duration of the study.
Family residence within 2 hours of Yale Medical Center with ability and willingness to attend assessment and fMRI visits.
Disqualifiers
Intelligence quotient below 80
Current diagnosis of autism spectrum disorder, bipolar or psychotic disorder or current suicidality
Significant medical condition such as heart disease, hypertension, liver or renal failure, pulmonary disease, seizure disorder
Recently initiated psychotherapy. Participation in the study will not be allowed within 8 weeks of the initiation of psychotherapy. Ongoing, concurrent psychotherapy (that was initiated at least 8 weeks previously) for the child will be allowed, but parents will be asked not to initiate any new psychotherapy for the child during the study
Trial design
Treatments tested in this trial
- Neurofeedback from the SMA
- Neurofeedback from control region
Treatment groups
64 Participants
are divided into 2 treatment groupsSponsors and collaborators
Yale University
Lead sponsor
National Institute of Mental Health (NIMH)
Collaborator
Source ClinicalTrials.gov